The impact of diagnosing provider type on longitudinal care for patients with newly diagnosed Huntington’s disease
Patients with HD are most often diagnosed by neurologists or PCPs; the same diagnosing provider type typically manages follow-up. Patients diagnosed by neurologists had significantly fewer HD-related outpatient visits, lower HD-related non-drug costs, and more frequently received VMAT2 inhibitors <i>vs.</i> those diagnosed by PCPs. Our findings show an integrated care team may provide evidence-based, personalized care for patients with HD.
Authors
- Eric Jen (ORCID: https://orcid.org/0000-0001-7322-2403)
- Michael Serbin (ORCID: https://orcid.org/0000-0001-6876-7150)
- Dietrich Haubenberger (ORCID: https://orcid.org/0000-0002-6233-8168)
- Olga Klepitskaya
- Sean C. Hinton
- Ryan N. Hansen (ORCID: https://orcid.org/0000-0003-3887-1242)
- Hyunwoo Kim (ORCID: https://orcid.org/0000-0001-6785-7760)
- Kyu-Eun Lee (ORCID: https://orcid.org/0000-0003-3102-5094)
Institutions
- University of Washington (US)
- Neurocrine Biosciences (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1080/13696998.2024.2412470
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Neurocrine Biosciences